Study to Evaluate 13 C Isotope Ratio Measurement for Urea Cycle Capacity Assessment
Pilot Feasibility Study in Healthy Subjects and Healthy Asymptomatic Subjects Genetically Disposed to Urea Cycle Disorders to Evaluate the Use of 13 C Isotope Ratio Measurement
1 other identifier
interventional
10
1 country
1
Brief Summary
In this short-term study a method for the evaluation of the metabolic competency of the urea cycle in vivo will be assessed. In order to monitor the efficacy of new treatment options for patients with urea cycle disorders and to monitor the severity of the disease, a reliable and safe quantitative method for the measurement of the urea cycle flux is required. Urea synthesis will be evaluated by administering sodium \[1-13C\]-acetate and measuring subsequent incorporation of \[13C\] label from Na-acetate into urea in healthy volunteers and asymptomatic subjects genetically disposed to urea cycle disorders.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2009
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2009
CompletedFirst Submitted
Initial submission to the registry
October 26, 2009
CompletedFirst Posted
Study publicly available on registry
October 27, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2009
CompletedJanuary 15, 2010
January 1, 2010
2 months
October 26, 2009
January 14, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Increase of [13C]urea AUC in plasma following oral administration of [13C ]-sodium acetate over baseline
Secondary Outcomes (1)
Cmax of absolute [13C]urea in plasma
Study Arms (1)
sodium [1-13C] acetate
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Group 1 + 2: Healthy subjects
- Group 3: Healthy asymptomatic subjects genetically disposed to urea cycle disorders
- All: age 18 to 50 years (adult)
- Written informed consent
You may not qualify if:
- Presence of acute infection
- Severe coagulopathy
- Severe systemic or chronic disease
- Pregnancy or lactation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CRS Clinical Research Services Mönchengladbach GmbH
Mönchengladbach, 41061, Germany
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Doris Neuenhofer, MD
CRS Clinical Research Services Mönchengladbach GmbH
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
October 26, 2009
First Posted
October 27, 2009
Study Start
September 1, 2009
Primary Completion
November 1, 2009
Study Completion
December 1, 2009
Last Updated
January 15, 2010
Record last verified: 2010-01